Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both ...
Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% year-over-year; regulatory submission for prefilled syringe ...
“Patients with pulmonary edema generally describe breathlessness. Sometimes they feel like they are suffocating or breathing ...
MedaSystems, the leading SaaS platform for Expanded Access, Post Trial Access, and Investigator Initiated Studies, today announced a milestone year defined by accelerated customer growth, strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback